Jefferies initiates buy on Krystal Biotech with a $245 price target, citing Vyjuvek's strong growth potential and proprietary ...

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the ...

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.

Krystal Biotech Inc (KRYS) reports robust financial performance with significant revenue growth and strategic advancements in gene therapy.

Q4 2024 Management View CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He ...